Apriori Bio
Apriori Bio offers a platform for creating variant-resilient vaccines and provides real-time insights to prepare for future outbreaks.
About Apriori Bio
Apriori Bio is a health security company, aimed at protecting humanity against viral threats. The company uses a unique technology platform that enables the creation of variant-resilient vaccines and provides real-time insights to prepare for future outbreaks. Apriori Bio focuses on designing new vaccines and antibody drugs to combat existing and potential viral variants. With its innovative approach, the company aims to ensure durable protection against rapidly evolving viruses
Company Facts
- Headquarters
- Boston
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00011_00050
- Funding Stage
- early_stage_venture
- Total Funding
- $51,100,000
- Last Funding Type
- grant
- Last Funding Date
- 2024-07-08
- Website
- aprioribio.com
Industries & Categories
Biotechnology, Clinical Trials, Life Science, Medical
Social Links
Canonical: https://fsome.com/organization/apriori-bio-92629 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.